ClinicalTrials.gg
Not yet recruitingNCT07483437Updated Jun 1, 2026

A Study of HS-20136-2 in Healthy Participants

A Phase 1 interventional study of HS-20136-2 injection and HS-20136-2 injection Placebo in Healthy, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a randomized, double-blind,placebo-controlled phase I clinical study.The main purpose is to assess the safety and tolerability of single subcutaneous administration of HS-20136-2 injection in healthy participants.

Read the detailed description

This is a phase I, double-blind, randomised, placebo-controlled trial to assess the safety and tolerability of HS-20136-2 in healthy participants. We enrolled adults (aged 18-65 years, both inclusive) with body-mass index [BMI] ≥25 kg/m2 and ≤35 kg/m2 in Australia. Eligible participants were randomly assigned to receive a single dose subcutaneous injection of HS-20136-2 or placebo. The primary endpoint is:

  1. Incidence, severity, and relationship to the investigational products of adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from the study;
  2. Changes in laboratory tests (hematology, urinalysis, blood biochemistry, coagulation function, etc.), vital signs, ECG results, etc., before and after administration.
02

Conditions studied

  • Healthy

Keywords

  • HS-20136-2,single ascending dose,safety,tolerability
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are able to sufficiently understand the study content, process, and potential adverse reactions, and voluntarily sign the form;
  2. Healthy men and women aged 18-65 years (inclusive);
  3. Body weight ≥ 50 kg (male) or ≥ 45 kg (female) and (BMI) within the range of 25-35 (inclusive) [BMI = body weight/body height2 (kg/m2)];

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Participants with a history of cardiovascular, respiratory, hepatic, renal, digestive tract, mental, neurological, hematological, immune, and metabolic abnormalities (such as unexplained recurrent hypoglycemia) and other diseases, and not suitable for the study as assessed by the investigator, such as: Childhood asthma (resolved),Depression (non-hospitalised, but potentially medicated in the past), Migraine, etc.
  3. Glycosylated (HbA1c) > 6.5% or fasting blood glucose ≤ 3.9 mmol/L (70 mg/dL) or ≥ 6.1 mmol/L (110 mg/dL) during the screening period;
  4. The (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total (TBIL) > 1.5 × during the screening period (except for cases of known Gilbert's Syndrome);
  5. Participating in any clinical study involving drugs or medical devices (except for those not receiving an drug or investigational device) within 3 months before screening or 5 half-lives (whichever is longer) before screening, or currently participating in a clinical trial;
  6. Treatment with systemic , immunomodulators, or chemotherapy within 3 months before screening or likely to receive them during the study;
  7. Known severe allergic disease, or known allergies to GLP-1R agonists or Retatrutide, or allergic constitution (allergies to various drugs and foods);
  8. With concomitant diseases that may significantly affect the absorption of drugs or nutrients as judged by the investigator, such as gastrointestinal diseases (e.g., active inflammatory bowel disease) and symptoms of gastrointestinal disorders; or any condition that might affect the absorption of drugs, such as subtotal or total gastrectomy, sleeve gastrectomy, gastric bypass surgery, and resection of any intestinal area;
  9. History of confirmed chronic pancreatitis or idiopathic acute pancreatitis, or serum amylase or lipase greater than the upper limit of normal at screening. A participant with a history of acute pancreatitis caused by gallstones may be included in the study if the participant has a cholecystectomy to resolve the problem;
  10. Have a history of symptomatic gallbladder disease within the past 2 years, defined by the presence of gallstones on an imaging study and abdominal pain attributed to the gallstones by the participant's physician; subjects who had a procedure to remove the gallstones and/or the gallbladder (cholecystectomy), with no long-term complications, are eligible for participation as long as the procedure was completed at least 3 months prior to screening;
  11. Diet or weight loss treatment within 3 months prior to administration (regardless of the reason) or having body weight change of more than 5% or a significant change in living habits within 3 months prior to administration;
  12. Other reasons for exclusion, as determined by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    HS-20136-2 injection

    Escalating doses of HS-20136-2 administered subcutaneously (SC) once in healthy participants.

    Drug: HS-20136-2 injection

  • Placebo comparator
    HS-20136-2 injection Placebo

    Placebo administered SC once in healthy participants

    Drug: HS-20136-2 injection Placebo

Interventions

  • DrugHS-20136-2 injection

    Administrated SC

  • DrugHS-20136-2 injection Placebo

    Administrated SC

06

What researchers measure

Primary outcomes

  1. Incidence of adverse event (AE)

    A summary of AEs

    Time frame: Time of Inform Consent Form to Day 57

  2. Incidence of serious adverse event (SAE)

    A summary of SAEs

    Time frame: Time of Inform Consent Form to Day 57

  3. AE leading to study discontinuation

    AE leading to study discontinuation

    Time frame: Time of Inform Consent Form to Day 57

  4. AE severity and relation with study drug

    AE severity and relation with study drug will be reported in the reported adverse events module

    Time frame: Time of Inform Consent Form to Day 57

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC)

    PK: AUC

    Time frame: Baseline to Day 57

  2. Pharmacodynamics (PD): glucose change

    Changes in fasting blood glucose

    Time frame: Baseline to Day 57

  3. Pharmacokinetics (PK): Tmax

    PK: Tmax

    Time frame: Baseline to Day 57

  4. Pharmacokinetics (PK): Cmax of HS-20136-2

    PK: Cmax of HS-20136-2

    Time frame: Baseline to Day 57

  5. Pharmacodynamics (PD):weight change

    Changes in body weight

    Time frame: Baseline to Day 57

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 19, 2026
StartEst.
May 15, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07483437
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 1, 2026

Study contacts

Thomas Metodey Polasek, PhD(Clinical.Pharmacology)
Contact
cmax@cmax.com.au
+61 458 162 715

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion